/ Active, not recruiting临床3期 A Prospective Multi center Randomized Double blind Parallel group Active controlled Phase III Study to Compare the Efficacy Safety and Immunogenicity of Regenix Biosciences Limited Insulin 30/70 with Eli Lillys bacteria based Human Insulin Basal Bolus Humulin 30/70 in Type I and Type II Diabetes patients - Interventional
A Prospective Multi center Randomized Double blind Parallel group Active controlled Phase III Study to Compare the Efficacy Safety and Immunogenicity of Regenix Biosciences Limited India Human Insulin Short acting Investigational drug Regenix Insulin R with the Eli Lilly s bacteria based Human Insulin Short acting Reference drug Huminsulin R in Diabetes mellitus Type 1 and Type 2 patients - Nil
A Prospective, Multi-center, Randomized, Double blind, Parallel-group, Active-controlled, Phase III Study to Compare the Efficacy, Safety and Immunogenecity of Regenix Biosciences Limited,India, Insulin Glargine 100units/mL (U-100) (Investigational drug) with Lantus® (Insulin Glargine) of Sanofi-aventis, India, (Reference drug) in Type I and Type II Diabetes patients - Nil
100 项与 Regenix Biosciences Ltd. 相关的临床结果
0 项与 Regenix Biosciences Ltd. 相关的专利（医药）
100 项与 Regenix Biosciences Ltd. 相关的药物交易
100 项与 Regenix Biosciences Ltd. 相关的转化医学
